Hebei Changshan Biochemical Pharmaceutical Co Ltd banner

Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255

Watchlist Manager
Hebei Changshan Biochemical Pharmaceutical Co Ltd Logo
Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
Watchlist
Price: 41.22 CNY 5.29%
Market Cap: ¥37.9B

P/OCF

785.6
Current
162%
More Expensive
vs 3-y average of 299.5

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
785.6
=
Market Cap
¥39.6B
/
Operating Cash Flow
¥48.2m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
785.6
=
Market Cap
¥39.6B
/
Operating Cash Flow
¥48.2m

Valuation Scenarios

Hebei Changshan Biochemical Pharmaceutical Co Ltd is trading above its 3-year average

If P/OCF returns to its 3-Year Average (299.5), the stock would be worth ¥15.71 (62% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-98%
Maximum Upside
No Upside Scenarios
Average Downside
86%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 785.6 ¥41.22
0%
3-Year Average 299.5 ¥15.71
-62%
5-Year Average 82.8 ¥4.34
-89%
Industry Average 25 ¥1.31
-97%
Country Average 18.3 ¥0.96
-98%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
CN
Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
37.9B CNY 785.6 -125.6
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 47.8 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 22.3 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 19.3 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 14.2 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 16.7 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.5 11.1
US
Pfizer Inc
NYSE:PFE
149.3B USD 12.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 8.2 16.4
P/E Multiple
Earnings Growth PEG
CN
Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
Average P/E: 21.5
Negative Multiple: -125.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

Higher than 98% of companies in China
Percentile
98th
Based on 6 232 companies
98th percentile
785.6
Low
0.2 — 9.8
Typical Range
9.8 — 36.5
High
36.5 —
Distribution Statistics
China
Min 0.2
30th Percentile 9.8
Median 18.3
70th Percentile 36.5
Max 266 666.7

Hebei Changshan Biochemical Pharmaceutical Co Ltd
Glance View

Market Cap
37.9B CNY
Industry
Pharmaceuticals

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates as a key player in the global pharmaceutical industry, with a focused mission of advancing healthcare through innovative biochemical products. Founded in the heartland of China's Hebei province, the company has carved out a niche for itself by specializing in the production of heparin, a critical anticoagulant used in preventing and treating blood clots. Through state-of-the-art biotechnology and substantial R&D investments, Changshan Biochemical has mastered the complex extraction and refining processes that transform raw materials, often sourced from porcine intestinal mucosa, into these essential, life-saving pharmaceuticals. This scientific prowess is not just an end in itself; it represents the backbone of the company's business model, driving both their product portfolio and revenue streams. The company's success is intricately tied to its ability to integrate vertically and scale efficiently, which enhances operational agility and cost management. Such vertical integration involves controlling multiple stages of production—from raw material sourcing and synthesis to finished product distribution—ensuring consistent quality and supply. Moreover, Hebei Changshan's strategic emphasis on innovation allows it to develop new formulations and applications for its biochemical products, expanding its market reach both domestically and internationally. Revenue generation is largely derived from hospital sales, direct pharmaceuticals sales, and partnerships with other biotech firms. By leveraging its biochemical expertise and maintaining robust industry relationships, Changshan Biochemical not only secures its financial performance but also positions itself as a dependable partner in the global healthcare supply chain.

Intrinsic Value
3.66 CNY
Overvaluation 91%
Intrinsic Value
Price ¥41.22
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett